Patients Medical Professionals Careers Investors Therapy Sites Global Sites About Us Research & Pipeline Therapies Global Impact Newsroom Therapies We develop therapies for serious medical conditions with few or no treatment options. Filter by: All Multiple Sclerosis Spinal Muscular Atrophy Biosimilars Biosimilars FLIXABI® FLIXABI® is an infliximab biosimilar referencing Remicade® approved in the European Union (EU). FLIXABI is indicated in the EU to treat: Rheumatoid arthritis: The reduction of signs and symptoms as well as the improvement in physical function in adult patients, in combination with methotrexate, with: Active rheumatoid arthritis, when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. Severe, active and progressive disease not previously treated with methotrexate or other DMARDs. SEE MORE About Us About Biogen A Leader In Multiple Sclerosis Executive Leadership Board of Directors History Manufacturing Biosimilars Positions & Policy Perspectives Contact Us Governance Research & Pipeline Pipeline Clinical Trials Access to Investigational Therapies BiogenScience Areas of Research Postdoc Program Collaborations Medical Research portal Therapies Multiple Sclerosis AVONEX® FAMPYRA® PLEGRIDY® TECFIDERA® TYSABRI® ZINBRYTA® Spinal Muscular Atrophy SPINRAZA® Biosimilars BENEPALI® FLIXABI® IMRALDI® Partnered GAZYVA® RITUXAN® Global Impact Science that matters Biogen Foundation Community Lab Supplier Diversity Grants Office Patients Medical Professionals Careers Investors Follow us on: Twitter LinkedIn Facebook YouTube Privacy Policy Terms & Conditions Sitemap Forward-Looking Statements Community Guidelines Contact Us © 2017 Biogen